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in cystic fibrosis patients with
massive haemoptysisTo the Editor:
Haemoptysis is a common complication of cystic fibrosis
(CF). It occurs in approximately 9% of patients and is usually
associated with older age (24.2  8.7 years) and more se-
vere disease (60% with FEV1 <40%) [1,2]. Haemoptysis
originates mostly in the orthotopic bronchial arteries,
namely, those arising from the descending aorta between
the fifth and sixth dorsal vertebrae. It can also originate in
ectopic or aberrant bronchial arteries and in those arising
from systemic vessels, such as the internal mammary ar-
tery, the thyrocervical trunk, brachiocephalic trunk, sub-
clavian, abdominal aorta, aortic arch, or inferior phrenic
arteries. Bronchial artery embolization (BAE) is the rec-
ommended treatment for massive haemoptysis; however,
given the variable nature of the bronchial arterial supply, it
may be difficult to identify the responsible vessels during
bronchial angiography, thus leaving the patient at risk of
relapse. In the last few years, several works have recom-
mended multidetector computed tomography angiography
(MDCT-A) before BAE, although not specifically in patients
with CF. This approach enables detection of the source of
bleeding in 63%e100% of cases before treatment [3,4]. We
report a case that illustrates the value of MDCT-A for
localization of aberrant bronchial arteries before
treatment.
A 23-year-old man diagnosed with CF presented at the
emergency room with haemoptysis of 250 mL/h. His geno-
type was G542X/unknown, and sputum had been colonized
by Burkholderia cenocepacia for 7 years. The patient had
pancreatic insufficiency. A lung function test 2 months
previously disclosed a forced vital capacity of 5.45 L (89%
predicted) and a forced expiratory volume in 1 s (FEV1) of
3.22 L (66% predicted). He was studied at the haematology
department for a 2-year history of polycythaemia that was
eventually considered to be of respiratory origin, and oxy-
gen therapy was started at 2 L/min. He had no symptoms of
exacerbation. Onset of haemoptysis was immediate after0954-6111/$ - see front matter ª 2014 Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.rmed.2013.12.010the physiotherapy exercises, with gurgling sounds in the
left hemithorax. Physical examination revealed arterial
blood pressure of 110/60 mmHg, mild tachypnea, oxygen
saturation of 96% on breathing room air, and no fever.
Auscultation revealed bilateral thick rales (lower hemi-
thorax). His laboratory values were as follows: red cells,
5.74 m/mm3; haemoglobin, 18.4 g/dL; and haematocrit,
52%. All other parameters were normal. A chest radiograph
revealed diffuse bilateral bronchiectasis similar to that
observed during preceding years. He received oxygen
therapy, tranexamic acid (500 mg/8 h), codeine, and anti-
biotic therapy (meropenem 2 g/8 h and ceftazidime 2 g/
8 h). A vascular interventional radiologist was contacted
and BAE performed at the site where the patient localized
the symptoms. Catheterization of the left bronchial artery
proved difficult, and only a partial procedure was achieved.
Haemoptysis persisted, and MDCT-A was performed.
Generalized bronchiectasis was visible on both lungs. Mul-
tiple enlarged and tortuous right-sided bronchial arteries
were detected in the posterior mediastinum; one of the
arteries had an anomalous origin, arising from the right
subclavian artery (Fig. 1(a)e(b)). The others were ortho-
topic, arising from the aortic arch and descending aorta.
Ground glass opacities were present on the right lung,
indicating the source of bleeding. The arteries were
embolized with polyvinyl alcohol (710e1000 mm) (Contour,
Boston Scientific, Natick, USA) because fistulas to the pul-
monary arteries were detected. The patient has remained
stable and free of haemoptysis since the procedure.
CFF consensus statement recommends BAE for clinically
unstable CF patients with massive haemoptysis. Although
this procedure can prevent bleeding in most cases, the
consensus provides no information on embolization strat-
egy [1,2]. The most commonly reported side effects of
embolization are chest pain (24e91%) and dysphagia
(1e18%). More serious complications include paralysis
caused by embolization of the anterior medullary artery
and pulmonary infarction. MDCT-A prior to BAE is a
contentious issue [2]. The CFF statement was unable to
make a recommendation because of insufficient evidence.
Hurt and Simmonds [5] think this may change in future
guidelines and that MDCT-A should be introduced before
BAE. MDCT-A is useful in planning the embolization proce-
dure (selection of catheter type and size, amount of
embolization material); it clearly shows the anatomy of the.
Figure 1 (a) Three dimensional CT reconstruction. The posterior view reveals the origin of an aberrant right bronchial artery
arising from the right subclavian trunk (arrow). (b) Selective catheterization of the aberrant bronchial artery.
Letter to the Editor 817thoracic vasculature, thus providing important information
for the interventional radiologist, as was the case in our
patient [4,5]. MDCT-A can replace the routine use of pre-
liminary flush aortography for determining the number and
site of abnormal arteries. It is also useful for identifying the
anatomical characteristics and severity of bleeding in the
bronchial arteries and verifying the indication for BAE [4,5]
MDCT-A before embolization has the potential to decrease
the duration of the procedure and exposure to radiation.
These advantages increase the overall efficiency of the
technique. We therefore recommend routine use of MDCT-
A before interventions in patients with CF and massive
haemoptysis.
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